BGB Group Revenue and Competitors

Location

N/A

Total Funding

Marketing

Industry

Estimated Revenue & Valuation

  • BGB Group's estimated annual revenue is currently $174.1M per year.(i)
  • BGB Group's estimated revenue per employee is $312,500

Employee Data

  • BGB Group has 557 Employees.(i)
  • BGB Group grew their employee count by 2% last year.

BGB Group's People

NameTitleEmail/Phone
1
Chief People OfficerReveal Email/Phone
2
Chief, Business IntegrationReveal Email/Phone
3
Associate VP, Medical Director, Medical Strategy and Scientific ServicesReveal Email/Phone
4
Chief Innovation and IntelligenceReveal Email/Phone
5
SVP, Brand StrategistReveal Email/Phone
6
VP, Group Management SupervisorReveal Email/Phone
7
SVP, Medical Strategy and Scientific AffairsReveal Email/Phone
8
SVP, Group Management SupervisorReveal Email/Phone
9
VP, Project ManagementReveal Email/Phone
10
VP, Management SupervisorReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$42.6M1550%N/AN/A
#2
$1436.1M4103-6%N/AN/A
#3
$19.3M777%N/AN/A
#4
$0.5M4-43%N/AN/A
#5
$21.5M866%N/AN/A
#6
$11.7M528%N/AN/A
#7
$1683.2M48095%N/AN/A
#8
$1197M3420-19%N/AN/A
#9
$24.8M999%N/AN/A
#10
$298.9M8543%N/AN/A
Add Company

What Is BGB Group?

BGB was founded in 2005 by two entrepreneurs: an MD internist and a marketing MBA. With commercial savvy and a passion for science, came a unique fusion of authoritative medical insights with breakthrough creative communications.\n\nToday, BGB is an independent agency of 300+ employees across 5 subsidiaries, BGBNYC, BIONYC, SCIONYC, ICONYC, SYNGENYC, that delivers the best in healthcare communications including medical and marketing consulting, promotional advertising, medical education and digital strategy and execution.

keywords:N/A

N/A

Total Funding

557

Number of Employees

$174.1M

Revenue (est)

2%

Employee Growth %

N/A

Valuation

N/A

Accelerator

BGB Group News

2022-04-20 - Tislelizumab plus chemotherapy significantly extends OS in ...

... seen in the tislelizumab and chemotherapy group in RATIONALE 306. ... Tislelizumab (BGB-A317, BeiGene), a humanized immunoglobulin G4...

2022-04-20 - FDA decisions on new oncological drugs

... single-arm pivotal phase 2 study (BGB-3111–206) conducted in China, ... The use of an optimal control group might increase the external...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$99.2M558-56%$34.2M
#2
$144.8M55952%$50M
#3
$90.8M559-10%N/A
#4
$35M559N/AN/A
#5
$69.9M5595%N/A